Regn stock price regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc. (REGN) stock price recently traded around $933.45, reflecting a slight intraday dip of 0.42% despite strong biotech sector sentiment. Analysts cite ongoing optimism around its eye disease drug Eylea but caution about competitive pressures from Roche and Novartis. Short-term technical charts show resistance near $950 and support around $910. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is engaged in discovering, inventing, developing, manufacturing, and commercializing medicines for treating various diseases. Dupixent® has been characterized as a critical growth driver for the company, with strong potential for further expansion. The drug’s efficacy throughout multiple inflammatory conditions as well as its favorable safety profile place it well for continued expansion into the new indications. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent® (dupilumab) in adults having moderate-to-severe bullous pemphigoid (BP). To provide a brief context, BP is a chronic, debilitating, and relapsing skin disease. Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies. REGN stock price closed flat at $934.21 despite higher crude oil prices impacting market sentiment. Defensive healthcare stocks like REGN often attract capital rotation during periods of macro uncertainty.